These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24952227)

  • 1. A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.
    Higuchi M; Honjo H; Shigihara T; Shishido F; Suzuki H; Gotoh M
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1957-63. PubMed ID: 24952227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
    Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
    Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors.
    Sharma A; Lanuti M; He W; Palmer EL; Shepard JA; Digumarthy SR
    J Comput Assist Tomogr; 2013; 37(1):9-14. PubMed ID: 23321827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
    Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
    Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors.
    Higuchi M; Suzuki H; Gotoh M
    PET Clin; 2016 Jan; 11(1):47-55. PubMed ID: 26590443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
    Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M
    J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual time-point (18)F-FDG PET/CT to assess response to radiofrequency ablation of lung metastases.
    Lafuente S; Fuster D; Arguis P; Granados U; Perlaza P; Paredes P; Vollmer I; Sánchez M; Lomeña F
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):226-31. PubMed ID: 26848142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Observation of CT-guided Radiofrequency Ablation of Lung Neoplasm in 476 Consecutive Patients by a Thoracic Surgical Service: A Single-institutional Experience.
    Huang BY; Zhou JJ; Yu ZQ; Song XY; Lin Y; Li XM; Li L
    Acad Radiol; 2017 Dec; 24(12):1517-1525. PubMed ID: 28888381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?
    Yoo DC; Dupuy DE; Hillman SL; Fernando HC; Rilling WS; Shepard JA; Siegel BA
    AJR Am J Roentgenol; 2011 Aug; 197(2):334-40. PubMed ID: 21785078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-session radiofrequency ablation of bilateral lung metastases.
    Palussière J; Gómez F; Cannella M; Ferron S; Descat E; Fonck M; Brouste V; Avril A
    Cardiovasc Intervent Radiol; 2012 Aug; 35(4):852-9. PubMed ID: 21647807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning.
    Blokhuis TJ; van der Schaaf MC; van den Tol MP; Comans EF; Manoliu RA; van der Sijp JR
    Scand J Gastroenterol Suppl; 2004; (241):93-7. PubMed ID: 15696856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
    Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
    J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.
    Deandreis D; Leboulleux S; Dromain C; Auperin A; Coulot J; Lumbroso J; Deschamps F; Rao P; Schlumberger M; de Baère T
    Radiology; 2011 Jan; 258(1):270-6. PubMed ID: 21045185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
    Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
    Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of pre-radiofrequency ablation SUV(max) in 18F-FDG PET/CT to predict the risk of a local recurrence of malignant lung tumors after lung radiofrequency ablation.
    Harada S; Sato S; Suzuki E; Okumura Y; Hiraki T; Gobara H; Mimura H; Kanazawa S; Kaji M; Fujiwara T
    Acta Med Okayama; 2011 Dec; 65(6):395-402. PubMed ID: 22189480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.
    Bonichon F; Palussière J; Godbert Y; Pulido M; Descat E; Devillers A; Meunier C; Leboulleux S; de Baère T; Galy-Lacour C; Lagoarde-Segot L; Cazeau AL
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1817-27. PubMed ID: 24042540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.